Want to see HK:2522 full AI Analyst Report?
2522 Stock Chart & Stats
HK$8.10
-HK$4.70(-9.29%)
At close: 4:00 PM EST
HK$8.10
-HK$4.70(-9.29%)
Day’s Range― - ―
52-Week RangeHK$3.74 - HK$24.44
Previous CloseN/A
Volume38.00K
Average Volume (3M)10.53M
Market Cap
HK$1.86B
Enterprise ValueHK$1.79B
Total Cash (Recent Filing)HK$626.16M
Total Debt (Recent Filing)HK$622.72M
Price to Earnings (P/E)380.0
Beta1.26
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding294,128,080
10 Day Avg. Volume6,254,929
30 Day Avg. Volume10,530,505
Financial Highlights & Ratios
PEG Ratio-6.51
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.06B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit RecoveryA return to revenue growth and a swing from a sizable loss to a positive net income indicate the business model can recover from shocks. This improves the firm's ability to invest, service obligations and rebuild margins, supporting durable operational stability over the next several quarters.
Operating Cash Flow ReboundA strong recovery in operating cash flow demonstrates renewed underlying cash generation, improving self-funding capacity for operations and capex. Sustained OCF reduces reliance on external funding and supports medium-term execution and liquidity resilience.
Manageable Leverage On Balance SheetA sizable equity base relative to debt provides financial flexibility to absorb shocks or fund growth without immediate refinancing pressure. This capital structure supports medium-term strategic options and reduces bankruptcy risk given current earnings and cash flow recovery.
Bears Say
Revenue And Earnings VolatilitySharp swings in top-line and bottom-line results indicate inconsistent demand or unstable operating performance. Such volatility undermines forecasting, makes margin improvement uncertain, and raises execution risk for sustaining profits over multiple quarters.
Free Cash Flow InstabilityLarge FCF swings suggest material sensitivity to capex or working-capital changes, reducing predictable cash available for dividends, debt reduction, or reinvestment. That variability increases financing risk and complicates long-term capital allocation decisions.
Rising Absolute Debt LevelsAn upward trend in debt raises interest and refinancing obligations, which can constrain strategic flexibility when profits are thin. Even with reasonable equity, growing leverage is a structural headwind for sustaining investment and shareholder returns if earnings do not reliably strengthen.
Jiangxi Rimag Group Co., Ltd. Class H News
2522 FAQ
What was Jiangxi Rimag Group Co., Ltd. Class H’s price range in the past 12 months?
Jiangxi Rimag Group Co., Ltd. Class H lowest stock price was HK$3.74 and its highest was HK$24.44 in the past 12 months.
What is Jiangxi Rimag Group Co., Ltd. Class H’s market cap?
Jiangxi Rimag Group Co., Ltd. Class H’s market cap is HK$1.86B.
When is Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date?
Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 25 days.
How were Jiangxi Rimag Group Co., Ltd. Class H’s earnings last quarter?
Jiangxi Rimag Group Co., Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.036.
Is Jiangxi Rimag Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangxi Rimag Group Co., Ltd. Class H’s price is currently Overvalued.
Does Jiangxi Rimag Group Co., Ltd. Class H pay dividends?
Jiangxi Rimag Group Co., Ltd. Class H does not currently pay dividends.
What is Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate?
Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangxi Rimag Group Co., Ltd. Class H have?
Jiangxi Rimag Group Co., Ltd. Class H has 294,128,080 shares outstanding.
What happened to Jiangxi Rimag Group Co., Ltd. Class H’s price movement after its last earnings report?
Jiangxi Rimag Group Co., Ltd. Class H reported an EPS of -HK$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.68%.
Which hedge fund is a major shareholder of Jiangxi Rimag Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2522
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangxi Rimag Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Jiangxi Rimag Group Co., Ltd. Class H
Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammography, serving both patients and other healthcare sector clients. It also offers sophisticated imaging solution services. Additionally, Rimag Cloud provides various digital offerings such as cloud-based storage and film modules, a cloud radiology information system (RIS), a cloud Picture Archive and Communication System (PACS), alongside modules for AI integration and operational management within imaging platforms. The firm also oversees and manages a medical imaging platform that hosts a diverse range of imaging-related services. Supporting its activities is a dedicated research and development center, and it further engages in the distribution of medical equipment and related consumables. Established in 2014, the company maintains its primary office in Beijing, China.
Technical Analysis
EuroEyes International Eye Clinic Limited
―
Chaoju Eye Care Holdings Ltd.
―
Yonghe Medical Group Co., Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―